Alkahest is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neurodegenerative and age-related diseases by leveraging insights from the plasma proteome. Their approach centers on "chronokines," which are proteins that fluctuate with age and play a critical role in the body's biological processes. By targeting specific chronokines, Alkahest aims to create therapeutics that can either promote natural restorative processes or inhibit harmful degenerative mechanisms associated with diseases such as Alzheimer's, Parkinson's, and Age-related Macular Degeneration (AMD). Their pipeline includes various clinical candidates, including selected plasma fractions and protein-targeted interventions, designed to address the detrimental effects of aging.

The company has made significant strides in understanding the human plasma proteome, identifying over 8,000 proteins that change with age. This comprehensive mapping facilitates the development of new therapeutic candidates and diagnostic tools. Alkahest's collaboration with Grifols, a leader in plasma-derived medicines, enhances their research capabilities and accelerates the translation of their findings into clinical applications. Their ongoing clinical trials, including those for GRF6021, demonstrate promising results in improving cognitive function in patients with Parkinson's disease and cognitive impairment, highlighting the potential of their plasma-based therapies in addressing unmet medical needs in age-related conditions.

United States

Alkahest, a subsidiary of Grifols, is developing therapies derived from blood to treat neurological diseases, with an emphasis on age-related cognitive decline -- key medical challenges of our generation. The company’s breakthrough research has demonstrated that factors in blood plasma of young mice are able to reverse brain deficits in normal aging and Alzheimer’s disease models in mice. Clinical studies are being conducted in patients with different types of dementia and other neurodegenerative diseases. Alkahest is based in San Carlos, Calif., while Grifols, a global healthcare company, is headquartered in Barcelona, Spain.

Central Nervous System (CNS)

Eye Diseases

Immune System Diseases

Kidney Diseases

Nervous System Diseases

Psychological Diseases

Alkahest

Parkinson's disease

Wet age-related macular degeneration

AKST4290

Small Molecule Pharmaceuticals

Alzheimer's disease

Post-operative pain management

AKST/GRF6019/6021

Biologics

Cognitive Dysfunction

Renal disease

AKST1210

Inflammatory disease

California - North

California

Regenerative Medicine

Therapeutic

Alkahest

Company Details